title: Protective effect of notoginsenoside R1 in a rat model of myocardial ischemia reperfusion injury by regulation of Vitamin D3 upregulated protein 1/NF-κB pathway.
abstract: The aim of this study was to investigate the protective effects of notoginsenoside R1 (R1) in the rat model of myocardial ischemia reperfusion injury and the possible mechanisms. Myocardial ischemia/reperfusion injury (MIRI) was induced by ischemia for 30 min and reperfusion for 60 min. Fifty male SD rats (250-300 g), were randomly divided into 5 groups: sham, model, R1 (20 mg/kg, 40 mg/kg, 60 mg/kg). The activities of serum lactate dehydrogenase (LDH), creatine kinase (CK), myeloperoxidase (MPO), total superoxide dismutase (T-SOD), and malondialdehyde (MDA) were determined after 60 min of reperfusion. Interleukin-1β (IL-1β), interleukin-8 (IL-8) and tumor necrosis factor (TNF)-α were evaluated by enzyme-linked immunosorbent assay (ELISA), Vitamin D3 Upregulated Protein 1 (VDUP1), IκB α, P-IκB α, NF-κBP65, pNF-κBP65 were measured by western blotting. Our study demonstrated that R1 can ameliorate the impaired mitochondrial morphology and oxidation system; IL-1 β, IL-8 and TNF-α were recovered. Western blotting studies demonstrated that R1 substantially inhibited p-IκBα, NF-κBP65, p-NF-κBP65 protein levels and increased VDUP1 protein level. These findings suggest that R1 may effectively ameliorate the progression of 1/R injury and could be used as a therapy for patients with myocardial ischemia/reperfusion injury.
authors.forename: Kun-Peng
authors.initials: KP
authors.lastname: Xia
authors.forename: Hua-Ming
authors.initials: HM
authors.lastname: Ca
authors.forename: Chang-Zhong
authors.initials: CZ
authors.lastname: Shao
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000187:drug effects; D018797:Cell Cycle Proteins; D003402:Creatine Kinase / Q000032:analysis / Q000378:metabolism; D036145:Ginsenosides / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000032:analysis / Q000378:metabolism; D008297:Male; D008929:Mitochondria, Heart / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D009203:Myocardial Infarction / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology / Q000648:ultrastructure; D016328:NF-kappa B / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D036145:Ginsenosides; D016328:NF-kappa B; C493796:TXNIP protein, rat; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; C072936:notoginsenoside R1